目的 探讨长春胺缓释胶囊联合依达拉奉右莰醇注射用浓溶液治疗急性脑梗死的临床效果。方法 收集大庆油田总医院2021年10月—2023年10月收治的105例急性脑梗死患者临床资料，依据治疗方案不同分为对照组（52例）和治疗组（53例）。对照组依达拉奉右莰醇注射用浓溶液15 mL与0.9%氯化钠注射液100 mL混合后静脉滴注，2次/d。治疗组在对照组基础上口服长春胺缓释胶囊30 mg/次，2次/d。两组均持续用药7 d。比较两组临床疗效、神经功能缺损情况、炎症因子和氧化应激指标。结果 治疗组总有效率高于对照组（P＜0.05）；治疗后，两组美国国立卫生研究院卒中量表（NIHSS）评分均降低（P＜0.05），且治疗组的NIHSS评分低于对照组（P＜0.05）。治疗后，两组血清白细胞介素-1β（IL-1β）、肿瘤坏死因子-α（TNF-α）、丙二醛（MDA）水平均降低，血清超氧化歧化酶（SOD）水平升高（P＜0.05），且治疗组炎症因子和氧化应激指标变化优于对照组（P＜0.05）。结论 在静脉滴注依达拉奉右莰醇注射用浓溶液基础上口服长春胺缓释胶囊可显著提高急性脑梗死患者临床疗效，有效改善神经功能缺损情况，降低炎症因子水平，减轻机体氧化应激损伤。

Objective To explore the clinical efficacy of Vincamine Sustained Release Capsules combined with Edaravone and Dexborneol Concentrated Solution for injection in treatment of acute cerebral infarction. Methods Clinical data of 105 patients with acute cerebral infarction admitted to Daqing Oilfield General Hospital from October 2021 to October 2023 were collected, and were divide into control group (52 cases) and treatment group (53 cases) according to different treatment plans. In the control group, 15 mL Edaravone Dexborneol Concentrated Injection was mixed with 100 mL 0.9% sodium chloride injection and administered via intravenous infusion over 30 minutes, twice daily. Patients in the treatment group were po administered with Vincamine Sustained Release Capsules at a dose of 30 mg/time on the basis of the control group, twice daily. Both groups of patients continued to take medication for 7 d. The clinical efficacy, neurological deficits, inflammatory factors, and oxidative stress indicators were compared between two groups. Results The treatment group exhibited a superior overall response rate relative to the control group (P < 0.05). Post-treatment evaluation revealed statistically significant reductions in NIHSS scores across both groups (P < 0.05), and the treatment group demonstrating markedly lower NIHSS scores compared to the control group (P < 0.05). After treatment, the serum levels of IL-1β, TNF-α, and MDA were decreased in both groups, while the serum level of SOD was increased (P < 0.05). Treatment group inflammation and oxidative stress index change was better than those in the control group (P < 0.05). Conclusion On the basis of intravenous infusion of Edaravone and Dexborneol Concentrated Solution for injection, oral Vincamine Sustained Release Capsules can significantly improve the clinical effect of acute cerebral infarction, effectively improve the neurological deficit, reduce the level of inflammatory factors, and alleviate oxidative stress damage.

R971

收稿日期：2024-08-21